Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19968516 | 0.81 | S1PR1 (0.51) | S1PR1S1PR3MAPTKDM4EALDH1A1 | |
| SCHEMBL19952957 | 0.80 | S1PR1 (0.50) | S1PR1S1PR3MAPTALDH1A1NPC1 | |
| SCHEMBL35210442 | 0.80 | S1PR1 (0.50) | S1PR1S1PR3MAPTALDH1A1NPC1 | |
| SCHEMBL21153218 | 0.80 | S1PR1 (0.47) | S1PR1S1PR3MAPTALDH1A1AOC3 | |
| SCHEMBL21152961 | 0.80 | S1PR1 (0.49) | S1PR1S1PR3MAPTALDH1A1NPC1 | |
| SCHEMBL21152963 | 0.79 | S1PR1 (0.49) | S1PR1S1PR3MAPTNPC1RAB9A | |
| SCHEMBL23987478 | 0.79 | S1PR1 (0.48) | S1PR1S1PR3MAPTKDM4EALDH1A1 | |
| SCHEMBL4739779 | 0.78 | S1PR1 (0.46) | S1PR1S1PR3MAPTKDM4EALDH1A1 | |
| SCHEMBL21152962 | 0.78 | S1PR1 (0.47) | S1PR1S1PR3MAPTNPC1RAB9A | |
| SCHEMBL21152964 | 0.77 | EPHX2 (0.49) | S1PR1S1PR3MAPTALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516029-B2 | Compounds for the treatment of Clostridium difficile infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2026-01-06 | — | — | US | disclosed |
| US-12054466-B2 | Compounds for the treatment of clostridium difficile infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2024-08-06 | — | — | US | disclosed |
| US-11168062-B2 | Compounds for the treatment of Clostridium difficile infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210340116-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-11-04 | — | — | US | disclosed |
| US-20210340117-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-11-04 | — | — | US | disclosed |
| US-20190210984-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2019-07-11 | — | — | US | disclosed |
| WO-2018049404-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210984-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | VNN1, NGLY1, NUCB2 | S1PR1 3916/4885S1PR3 4424/4885MAPT 2752/4885 |
| US-12054466-B2 | Compounds for the treatment of clostridium difficile infection | VNN1, NGLY1, NUCB2 | S1PR1 3916/4885S1PR3 4424/4885MAPT 2752/4885 |
| US-11168062-B2 | Compounds for the treatment of Clostridium difficile infection | VNN1, NGLY1, NUCB2 | S1PR1 3916/4885S1PR3 4424/4885MAPT 2752/4885 |
| US-20210340117-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | VNN1, NGLY1, NUCB2 | S1PR1 3916/4885S1PR3 4424/4885MAPT 2752/4885 |
| US-20210340116-A1 | COMPOUNDS FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION | VNN1, NGLY1, NUCB2 | S1PR1 3916/4885S1PR3 4424/4885MAPT 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.